ProQR Therapeutics
PRQR
47 hedge funds and large institutions have $15.9M invested in ProQR Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 12 closing their positions.
4,000% more call options, than puts
Call options by funds: $41K | Put options by funds: $1K
1.25% less ownership
Funds ownership: 31.05% → 29.8% (-1.2%)
8% less capital invested
Capital invested by funds: $17.2M → $15.9M (-$1.35M)
8% less funds holding
Funds holding: 51 → 47 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$522K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$301K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$150K |
| 4 |
Two Sigma Advisers
New York
|
+$94.3K |
| 5 |
Morgan Stanley
New York
|
+$63.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$771K |
| 2 |
Renaissance Technologies
New York
|
-$272K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$168K |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$128K |
| 5 |
Jane Street
New York
|
-$104K |
PRQR Hedge Fund Activity: Q3 2022 in Review
47 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2022, worth a combined $15.9M — down 7.8% from $17.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PRQR and 8 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 8 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $522K. The largest seller was JP Morgan Chase, cutting an estimated $771K.
- 47 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2022, down from 51 in Q2 2022.
- Funds reported $15.9M of ProQR Therapeutics stock for Q3 2022, down 7.8% quarter-over-quarter.
- 8 funds opened new ProQR Therapeutics positions in Q3 2022 and 12 closed out, a net change of -4 holders.
- The largest ProQR Therapeutics buyer in Q3 2022 was DAFNA Capital Management, an estimated $522K added.
- The largest ProQR Therapeutics seller in Q3 2022 was JP Morgan Chase, an estimated $771K sold.
Based on aggregated 13F filings for Q3 2022.